Across TCGA pan-cancer cohorts, CEP290 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEP290 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP290 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP290 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CEP290 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.979	0.903	.015	21	view →
HNSC	OS	Median	All	0.161	1.000	.014	20	view →
CCRCC	DFS	Median	III,IV	0.431	0.731	.011	9	view →
PDAC	DFS	Quartile	All	0.312	0.595	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CEP290 tumor-vs-normal RNA expression · all CEP290 data types